Company intelligence / Profile preview
Mitsubishi Chemical Group
- Ownership
- Private
- Employees
- ~70000
- Development stage
- Other
Overview
Mitsubishi Chemical Group, primarily via its subsidiary Mitsubishi Tanabe Pharma, has a diverse pharmaceutical and healthcare portfolio. It markets several approved drugs globally—including treatments for ALS, diabetes, and rare diseases—and maintains an active R&D pipeline spanning from preclinical to Phase III/NDA stages. Recent highlights include global Phase III studies in rare diseases such as erythropoietic protoporphyria and regulatory submissions/approvals in Japan, North America, Europe, and China.
- Therapeutic areas
- Rare DiseasesNeurologyInfectious DiseasesEndocrinologyNephrologyImmunologyRheumatology
- Modalities
- Small moleculeBiologicVaccine
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Mitsubishi Chemical Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mitsubishi Chemical Group.